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Abstract
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Glioblastoma Multiforme (GBM) is the most common and invasive form of malignant brain
tumors and despite advances in surgery, radiotherapy and chemotherapy, the survival of patients
with GBM still remains poor. Temozolomide (TMZ) is the chemotherapy drug that is most
commonly given orally after surgical resection of these tumors. In this study, the effects of
solvents (i.e. dichloromethane and acetonitrile) used for the fabrication of electrosprayed TMZloaded poly(lactic-co-glycolic acid) (PLGA) on drug loading, loading efficiency, drug release
kinetics, surface morphology and particle size were investigated. The results from this study
demonstrated that by using a larger volume of a solvent with higher polarity (i.e. acetonitrile)
which allows for a higher amount of hydrophilic TMZ to dissolve into the polymer solution,
higher drug loading could be achieved. However, the particles fabricated with high amount of
acetonitrile, which has a lower vapor pressure, had large pores and a smaller diameter which led to
an initial burst release and high cumulative release at the end of the study. An optimal combination
of the two solvents is needed to result in particles with a good amount of loading and minimal
initial burst release. The electrosprayed microparticles were able to illicit a cytotoxic response in
U-87 MG glioblastoma cells at a lower concentration of drug compared to the free drug. This work
indicated that electrospraying is a promising method for the fabrication of TMZ-loaded PLGA
microparticles for the treatment of GBM and solvent composition can be altered to control drug
loading and release kinetics.
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INTRODUCTION
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Gliomas are the most common malignant brain tumors (70–80% of primary malignant brain
tumors) and Gliobastoma Multiforme (GBM) is the most prevalent, aggressive and highgrade form of these brain tumors (82% of malignant gliomas) [1]. Each year, around 10,000
patients in the US are diagnosed with GBM and currently the median survival for this
disease is around 21 months after diagnosis despite treatment with surgery, radiotherapy and
chemotherapy [2]. Gliomas are usually treated by resection surgery and external beam
radiation and occasionally by systemic chemotherapy or a combination of these methods [3].
For brain cancer, metastasis to other sites outside of the central nervous system (CNS) does
not occur very frequently and local recurrence is the main cause of death for this disease [4].
Due to the infiltrative nature of these tumors, it is difficult for surgeons to completely
remove the cancer cells without the risk of neurological deficits [5]. Thus, finding advances
in treating the residual disease to prevent local recurrence in brain cancer patients after
tumor resection should be an emphasis to increase the long term survival or possibly the
complete cure of patients [6].

Author Manuscript

Systemic delivery of chemotherapy and other anti-neoplastic agents, which can inhibit or
halt the progression of tumors, such as immunotherapy or anti-angiogenic drugs, have long
been a method of treatment for cancer, However, many shortcomings associated with
systemic delivery of these agents, including low local drug concentration at the targeted
tumor site, non-target cell and organ toxicity as well as low efficacy of the delivered drug
due to its short half-life, has emphasized the need for an alternative approach to replace this
method of delivery. For brain malignancies, an added challenge is present for systemic
delivery. Drugs for the treatment of these tumors also have the obstacle of having to cross
the Blood Brain Barrier (BBB). Although some chemotherapy agents, such as the classes of
anti-proliferation alkylating agents temozolomide (TMZ) and nitrosoureas (BCNU and
lomustine, are able to cross the BBB to some extent and have been used clinically [7], the
efficacy of these drugs even as a concurrent treatment to radiotherapy has been modest [8–
10]. The insufficient improvement in patient prognosis with these drugs is partly due to the
low local drug concentrations at the targeted site due to the inadequate delivery of the drugs
in spite of being able to cross the BBB [11, 12].
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By delivering drugs locally, the drug concentration at the tumor environment can be
maximized, non-target systemic exposure and organ toxicity can be minimized and the need
of finding a method to cross the BBB can be avoided. Furthermore, local delivery can
increase the efficacy of the drug as it can bypass the harsh environment and longer journey it
has to take to reach the targeted site of interest. The development of new drugs is associated
with high cost and difficulty. Thus, it would be beneficial if new treatment methods are
developed to successfully deliver currently available therapeutic agents that have been
shown to be promising in vitro, however, failed or resulted in modest outcomes when
delivered in vivo systemically. When designing a successful drug delivery system, different
factors such as the drug concentration, exposure time and drug administration schedule and
sequence of delivery have to be taken into account and all these factors will differ based on
the drug of interest. Biomaterials, such as disc, wafers and microparticles, can be optimally
designed and utilized to accomplish this for different drugs. Compared to scaffold materials
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such as disc and wafers, microparticles can be beneficial as it can be easily implanted to
discrete areas by stereotaxy instead of requiring open surgery [13].
TMZ is currently the chemotherapy drug that is most commonly given after surgical
resection of malignant glioma tumors through oral administration [2, 14] and has replaced
BCNU as the standard therapy for GBM as it is associated with less side effects and better
bioavailability compared to BCNU [15]. TMZ is an imidazotetrazine class DNA alkylating
agent that functions by methylating guanine and adenine bases of DNA which results in the
breaking of DNA double-strands and cell cycle arrest, leading to cell death [16]. Because
TMZ is an unstable molecule with a short half-life and dose-limiting side effects [17], the
current method of delivering TMZ alone systemically still produces modest benefits [18].
Thus, new strategies such as those employing biomaterials to protect the drug and enhance
the delivery of bioactive drug to the cancer cells are much needed.
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The co-polymer poly(lactic-co-glycolic acid) (PLGA) is an α-hydroxy acid-derived
polyester that has been widely used due to its inert properties, great biocompatibility and
versatility and thus, making it the most common material that is used for the fabrication of
biodegradable microparticles. PLGA has been shown to have biocompatibility in the brains
of rodents and human [19, 20]. The degradation rate of PLGA can be easily tailored from
days to years by tuning the lactic to glycolic acid ratio, molecular weight and the end cap
groups and thus, providing versatility in the development of microparticles to deliver
different drugs where the release kinetics need to be tailored to fit the drug of interest.
Because of its versatility and biosafety, PLGA has been widely used for the fabrication of
TMZ-loaded particles for the treatment of glioblastoma [21]. There are many different
methods of producing PLGA microparticles including emulsion solvent extraction/
evaporation [22], electrospraying [23] and microfabrication [24]. Among the different
fabrication methods, the emulsion solvent extraction/evaporation method is the most widely
used method for the fabrication of drug loaded microparticles as it is associated with an easy
and low cost setup [25–27]. However, the disadvantage of this technique is that it results in a
large loss of drug to the surrounding solutions during the fabrication process which results in
low entrapment efficiency and drug loading [24]. To overcome this, Zhang et al. saturated
the aqueous emulsion phase with 0.5 wt/vol % of drug (i.e. 400 mg of drug per synthesis of
a standard batch of particles), resulting in the use of a lot of drugs which can be very costly
[18]. Lee et al. who tried altering different parameters of fabrication of nanoparticles using
the emulsion solvent extraction/evaporation method were not successful at obtaining high
entrapment efficiency and drug loading and thus, concluded that the emulsion solvent
evaporation method of fabrication of TMZ-loaded microparticles is not efficient and other
method should be utilized to fabricate these particles [28]. Anata et al. investigated different
emulsion solvent extraction/evaporation techniques (i.e. single and double emulsion) for the
fabrication of TMZ/PLGA nanoparticles. They found that by using a single emulsion
technique with TMZ saturation in the aqueous phase, they were able to increase loading
efficiency by 90–700% and the encapsulation efficiency by 2–15-fold. However, even with
this significant increase in loading efficiency with their method, they concluded that the
loading efficiency of the particles still needs to be significantly improved to make it suitable
for TMZ delivery to treat glioblastoma patients [29]. Zhang et al have shown that TMZ
loaded PLGA microparticles synthesized by the emulsion solvent extraction/evaporation
J Biomed Mater Res B Appl Biomater. Author manuscript; available in PMC 2020 October 01.
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have been shown to improve the survival time of animals bearing intracranial tumor [30].
However, to achieve this, a lot of drug was needed to fabricate the particles as the aqueous
phase has to be saturated with the drug [30]. Thus, there is a need to find new methods to
fabricate TMZ loaded PLGA particles to result in high drug loading and entrapment
efficiency in order to improve the response of glioblastoma cells to these type of particles.
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Thus, the objective of this study was to investigate the utilization of the electrospraying
technique to fabricate TMZ-loaded PLGA microparticles with high drug loading and loading
efficiency. This method requires a pump, a syringe and needle with high electric potential
and a grounded electrode. A high voltage potential on the needle forces the polymer solution
out of the syringe and results in the formation of a jet that breaks into monodisperse droplets
which form the microparticles. Electrospraying is associated with many advantages
including the ability to fabricate particles with narrow size distribution, its experimental
setup requires low investment and it allows for scalable fabrication [31, 32]. A main reason
for using electrospraying instead of the common emulsion solvent extraction/evaporation
technique is that electrospraying is associated with high entrapment efficiency [32]. The
effects of solvent used for fabrication (i.e. different volume ratio of dicholoromethane
(DCM) and acetonitrile) of TMZ-loaded PLGA microparticles fabricated by electrospraying
on drug loading, loading efficiency, drug release kinetics, surface morphology and particle
size were determined. The particles were also tested on U-87 MG glioblastoma cells to
determine their ability to induce cytotoxicity in these cells. To the best of our knowledge,
this is the first manuscript that investigated the electrospraying method for the fabrication of
TMZ-loaded PLGA microparticles.

MATERIALS AND METHODS
Author Manuscript

Materials
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U-87 MG glioblastoma cells were obtained from American Type Culture Collection (ATCC,
Manassas, VA, ATCC® HTB-14™). Dulbecco’s Modified Eagle Media (DMEM) with high
glucose, l-glutamine and sodium pyruvate was purchased from Caisson’s Lab (Smithfield,
UT). Fetal bovine serum (FBS) Premium Select was obtained from Atlanta Biologicals.
Penicillin-streptomycin was obtained from GE Healthcare Life Sciences HyClone
Laboratories (Logan, UT). Methyl tetrazolium (MTT) powder and DCM were obtained from
Sigma-Aldrich (St. Louis, MO). Acetonitrile was purchase from VWR (Radnor, PA).
Dimethyl sulfoxide (DMS) was obtained from Fisher Scientific (Hampton, NH). PLGA
50:50 and (LP-779, Internal Viscosity = 0.43 dL/g, MW = 61 kDa) with an acid end group
was obtained from Evonik Industries (Birmingham, AL). TMZ was purchased from TCI
America (Portland, OR).
Fabrication of Electrosprayed PLGA Microparticles
PLGA microparticles loaded with TMZ were fabricated by electrospraying. Two different
solvents, DCM and acetonitrile were investigated by themselves or in combination. The four
different solvent combination that were fabricated are listed in Table 1 which are denoted as
1) “TM-0” which was fabricated with 0% DCM and 100% acetonitrile, 2) “TM-25” which
was fabricated with 25% DCM and 75% acetonitrile, 3) “TM-50” which was fabricated with
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50% DCM and 50% acetonitrile and 4) “TM-100” which was fabricated with 100% DCM
and 0% acetonitrile. The electrospraying setup consists of a Legato 100 Single Syringe
Pump (KD Scientific, Holliston, MA), ES30P-5W power supply (Gamma High Voltage
Research, Ormond Beach, FL), a copper collector plate and a glass syringe with a 21-gauge
blunt needle tip (Hamilton, Reno, NV). A 10 mm needle-tip to copper plate distance was
used. The pump speed of 2 mL/hr was used with a voltage of 6 kV. Briefly, for the four
different types of microparticles, 200 mg PLGA (5 wt/vol %) and the amount of drug shown
in the table were dissolved in a total of 4 mL of solvent. The particles were fabricated with a
temperature and humidity range of 22–24°C and 45–50%, respectively. The amount of drug
used for fabricating the microparticles were based on the maximum amount of TMZ that
would dissolve into the different solvent combinations as shown in Table 1 (i.e. 20, 15, 10
and 4 mg in 4 mL of solvent for TM-0, 25, 50 and 100, respectively). The electrosprayed
microparticles were collected directly on the copper plate and dried under vacuum for 24
hours to ensure complete removal of the solvent.
Drug Loading and Loading Efficiency
The amount of drug loaded into the microparticles was determined using a previous protocol
with some modification [18]. 5 mg of microparticles were completely dissolved in 2.5 mL of
DMSO (100%). The amount of TMZ loaded into the microparticles was determined by
measuring the absorbance at 327 nm with a microplate reader equipped with the Magellan
data analysis software (Tecan Infinite Pro 200, Switzerland). The drug loading and loading
efficiency analyses were done in triplicate. The drug loading and loading efficiency were
determined with the equations below.
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Drug loading (%) =

Loading efficiency (%) =

weight of drug in sample
⋅ 100
total weight of sample

actual amount of drug loaded
⋅ 100
theorectical amount of drug loaded

Drug Release Kinetics
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2.5 mg of microparticles were placed in 1 mL of PBS in a scintillation vial at 37°C and
shaken at 70 rpm. At each time point (0, 1, 4, 7, 10, 14 d), the PBS was removed from the
scintillation vials and the amount of TMZ was obtained as described above. Due to the
instability of the TMZ in the release solution, the TMZ release in the solution was not
measured and instead, the amount of TMZ remaining in the microparticles was used to
calculate the cumulative release at each time point [33]. This study was conducted at n = 3.

% Cumulative Release at time X =

sum of drug released up to time X
⋅ 100
total amount of drug loaded
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The microparticle surface morphology was observed by Scanning Electron Microscopy
(SEM) using a JSM-7100FA Analytical Field Emission SEM and Energy Dispersive X-Ray
analysis System (EDS) (JEOL USA Inc., Peabody, MA). SEM images were taken using an
electron beam with 5 kV and 6 kV. The microparticles were sputter coated with a 5 nm gold
layer using a smart coater (JEOL) to generate electrical conduction coating on the sample
surfaces.
Microparticle Size Determination
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The diameter of the microparticles was determined from 2000× SEM images using the NIH
Image J Software. For each image, the Feret diameter [34] of particles that the whole
particle could be clearly identified in the images (i.e. not covered by other particles) was
determined.
Cell Viability
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An MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma
Aldrich, St. Louis, MO) was used to analyzed the cytotoxicity of TMZ in the human U-87
MG glioblastoma cell line as previously described for testing of microparticles [33]. The
U-87 MG glioblastoma cells were cultured in DMEM media supplemented with 10% FBS,
100 U/mL penicillin and 100 μg streptomycin at 37°C, 5% CO2 and 90% relative humidity.
The cells were plated in a 96-well plate at a cell density of 1 × 104 cells/100 μL per well.
After allowing the cells to attach overnight, the media in each well was replaced with 100 μL
of media containing free TMZ powder, empty PLGA microparticles or TMZ-loaded PLGA
microparticles. Wells containing only media was used as a control. After 72 hrs, an MTT
assay was performed to determine the ability of the drugs to induce cytotoxicity in
glioblastoma cells. Briefly, the media in each well was replaced with 100 μL of 0.5 mg/mL
of MTT solution. After 3 hours, the MTT solution was removed and 100 μL of DMSO was
added to each well to dissolve the formazan salts that was formed by live cells by
metabolizing the MTT. The absorbance at 570 nm was determined with a microplate reader
equipped with the Magellan data analysis software (Tecan Infinite Pro 200, Switzerland).
Four wells were used for each condition (n=4) and the following equation was used to
determine cell viability (%).

Cell viability (%) =

absorbance of test cells
⋅ 100
absorbance of control cells

Author Manuscript

Statistical Analysis
Multiple-factor analysis of variance (ANOVA) was conducted to identify if there were any
significant differences among groups (p < 0.05) followed by the use of Tukey’s Honestly
Significantly Different (HSD) test to identify the specific groups that differed statistically
significantly.
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RESULTS
Drug Loading and Loading Efficiency
The drug loading and loading efficiency of the four different types of microparticles are
reported as percentages in Table 1. Particles fabricated with 0, 50, 75 and 100% DCM (i.e.
TM-0, TM-50, TM-75 and TM-100) resulted in a drug loading of 6.60 ± 0.20, 5.25 ± 0.21,
3.88 ± 0.21 and 1.38 ± 0.14%, respectively. The drug loading of each of the different types
of microparticles were significantly different from one another. The loading efficiencies of
the different microparticles were between 70–82% and were not significantly different from
each other.
Drug Release Kinetics
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The drug release kinetics of the different types of microparticles that were fabricated are
shown in Figure 2. The microparticles that were fabricated with a higher volume of
acetonitrile resulted in significantly higher % cumulative release (65.7 ± 8.2 and 69.3
± 4.6% for TM-0 and TM-25, respectively) at the end of the release study (i.e. Day 14)
compared to those fabricated with a lower amount of acetonitrile (27.4 ± 9.6% for TM-100).
Furthermore, TM-0 and TM-25 microparticles which were fabricated with a higher volume
of acetonitrile had a higher initial burst release (50.6 ± 1.6 and 57.9 ± 5.7%, respectively)
compared to TM-50 and TM-100 (19.4 ± 10.1 and 0 ± 0%, respectively).
Microparticle Size and Morphology
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SEM images of TM-0 and TM-25 show spherical microparticles with a porous surface of
size reaching up to 1 micron (Figure 1A and B). TM-25 in addition to spherical particles
shows traces of deformed biconcave disc microparticles indicating the beginning of a
transformation process. TM-50 microparticles (Figure 1C) had a biconcave disc shape while
further magnification show a nano-porous surface and TM-100 microparticles (Figure 1D)
had irregular and stretched out shapes with a rough non-porous surface. Xie et al. saw
similar morphologies for their PLGA and PCL microparticles that were fabricated by
electrohydrodynamic atomization (EHDA). As polymer concentration decreased, the shape
of the particles they fabricated changed from sphere to biconcave to an irregular shape [13].
Overall, with an increase in the amount of DCM and a decrease in the amount of acetonitrile
used for the solvent, the size of the particles increased (2.94 ± 0.76, 3.51 ± 0.71, 4.28 ± 1.13
and 11.50 ± 3.39 μm for TM-0, TM-25, TM-50 and TM-100, respectively). The particle size
of TM-50 and TM-100 were significantly larger compared to TM-0 and TM-25.
Cell Viability
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To test the response of glioblastoma U-87 MG cells to TMZ alone, empty PLGA
microparticles and TMZ-loaded PLGA microparticles were determined using an MTT assay.
TM-25 microparticles were used as an initial proof-of-concept of the bioactivity of the drug
loaded in the electrosprayed TMZ-loaded PLGA microparticles. Empty PLGA
microparticles did not illicit a negative response on cell viability of the glioblastoma cells
(Figure 3A). Cells exposed to TMZ by itself (66.7 ± 7.5 and 62.3 ± 7.2%, respectively) or
TMZ-loaded PLGA microparticles (74.1 ± 5.2 and 45.5 ± 3.0%, respectively) had a
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significantly lower % cell viability compared to empty microparticles (119.5 ± 3.1 and 119.0
± 7.9%, respectively) at a concentration of 500 and 1000 μM. At a drug concentration of
1000 μM, the TMZ-loaded PLGA microparticles had a significantly lower % cell viability
(45.5 ± 3.0%) compared to TMZ delivered by itself (62.3 ± 7.2%). For the results shown in
Figure 3A, the drug concentration of the TMZ-loaded microparticles are the amount of drug
that was loaded in the particles and not the actual amount that was present in the media and
exposed to the cells. Thus, for better comparison, in Figure 3B, we compared the cell
viability of cells exposed to TMZ by itself and TMZ-loaded microparticles based on the
amount of TMZ that had been released into the media based on the release study. For this
comparison, we observed that starting at 100 μM, cells exposed to TMZ-loaded
microparticles resulted in significantly lower cell viability (74.1 ± 5.2%) compared to TMZ
delivered by itself which had no effect on the cell viability (100.9 ± 8.9%). At a
concentration of 200 μM, cells exposed to TMZ loaded microparticles resulted in a cell
viability of 45.5 ± 3.0% whereas cells exposed to TMZ by itself resulted in a cell viability of
83.5 ± 9.2%.

DISCUSSION
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The emulsion solvent evaporation technique of fabricating microparticles is often used to
fabricate PLGA microparticles due to its low cost and ease in setup. However, this method
often results in high loss of drug to the external aqueous phase by diffusion, which leads to
low drug loading and loading efficiency. Thus, in this work, we investigated the utilization of
the electrospraying technique to fabricate TMZ-loaded PLGA microparticles with higher
drug loading and loading efficiency for the treatment of glioblastoma. The effects of altering
the solvent used for the fabrication of the microparticles on drug loading, loading efficiency
and release kinetics and particle size and morphology were studied. The two solvents that
were investigated were DCM and acetonitrile which have a relative polarity of 0.309 and
0.460, respectively. Due to its hydrophilic nature [29], TMZ more readily dissolves in
acetonitrile which is a more polar solvent. Solvent combinations with a higher volume of
acetonitrile were able to incorporate a higher amount of drug in the electrospraying polymer/
drug/solvent solution as TMZ dissolved better in the solvent (Table 1). This resulted in
significantly higher drug loading for microparticles fabricated with more acetonitrile
compared to microparticles fabricated with less acetonitrile as a higher starting drug
concentration could be used to fabricate the particles. The four different microparticles
fabricated by electrospraying had loading efficiency of 70–82%. Zhang et al. was able to
achieve an entrapment efficiency of around 62–85% with emulsion solvent evaporation
method by saturating the aqueous phase and thus, using a lot of drug during the fabrication
process [33]. Without saturation, the drug diffuses easily into the aqueous phase and the
entrapment efficiency that was achieved by them was only around 30%. Instead of using
only 4–20 mg of drug for fabrication with the electrospraying technique to achieve high drug
loading and loading efficiency, an additional 400 mg of drug is needed to saturate the
aqueous phase if the emulsion solvent evaporation method was used.
Particle porosity (i.e. pore size and amount of pores) can play a role in the release kinetics of
drugs from particles [35]. As determined by SEM, the porosity of the microparticles
changed with the different solvent used for fabricating the particles. The porosity of particles
J Biomed Mater Res B Appl Biomater. Author manuscript; available in PMC 2020 October 01.
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usually increases with a decrease in solvent extraction rate [25]. In our study, we saw that an
increase in acetonitrile volume and decrease in DCM volume resulted in higher pore size.
Acetonitrile and DCM have a vapor pressure of 97 and 475 hPa at 20°C, respectively. A
solvent with a higher vapor pressure exerts more pressure on the liquid phase resulting in
higher volatility or ease of vaporization. During fabrication, the lower volatility of
acetonitrile resulted in slower extraction of the solvent, and thus, resulted in the larger pores
and porosity for particles with higher portions of acetonitrile. Porosity in microparticles can
be created intentionally using porogens such as gelatin, PBS [36] or gas-forming agents or
can be created as an artifact of the fabrication technique which can also be created such as
the loss of absorbed oil that leaks out of particles after hardening [37] or during the freeze
drying step at the end of the fabrication process [38]. In our study, the pores in the
microparticles were created as an artifact of the solvent evaporation process as the particles
travel to the copper collection plate during fabrication. Several studies have shown that
microparticle porosity can result in initial burst release of drugs due to pore diffusion [39,
40]. Rapid initial release of drug often occurs due to the hydration of the outer wall of the
particles which leads to leaching of the drug [25]. Surface porosity of PLGA microparticles
plays an essential role in determining the magnitude of this initial release due to pore
diffusion [39]. Consistent with this, we saw that particles with large pores (TM-0 and
TM-25) resulted in a high burst release compared to particles with small pores (TM-50) or
no pores (TM-100) on their surface.
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Surface morphology and porosity of the microparticles can also affect the rate of erosion of
particles [41, 42]. The different microstructure of the microparticles that are created during
the fabrication process results in a difference in the accumulation of acidic degradation
byproduct of polyesters such as PLGA. These acidic byproducts play a role in further
catalyzing degradation of the microparticles. The release of drugs from PLGA
microparticles is initially dependent on diffusion through pores and channels, resulting in the
initial burst release. As the internal porosity decreases overtime, the polymer matrix
becomes denser. The release of the drug then starts to depend on erosion of the polymer and
not so much on diffusion.
In addition to facilitating drug release and degradation of the particles, the pores on the
surface of these microparticles are advantageous for our applications as they facilitate cell
attachment [36]. Increase in interaction of the cells and particles will more likely result in
the cancer cells uptaking the drug released from the particles.
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Besides a different in porosity characteristic with change of solvent ratio, the size of the
microparticles fabricated in this study also differed, which can also play a role in the release
kinetics of the drug loaded. Particles that are smaller in size usually result in a high initial
burst and/or fast release of the drug as these particles have higher surface area [43, 44]. Xie
et al demonstrated that smaller PLGA microparticles fabricated by electrohydrodynamic
atomization were obtained when acetonitrile was used instead of DCM [13]. We similarly
saw that a higher ratio of acetonitrile compared to DCM resulted in smaller particle size.
DCM and acetonitrile have a dielectric constant (indicating conductivity of the solvent) of
9.1 and 37.5, respectively [13]. There is a positive correlation between dielectric constants
and conductivity and thus, acetonitrile, which has a higher dielectric constant, has a higher
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conductivity compared to DCM which has a lower dielectric constant. As seen by Xie et al,
fabrication of particles with polymer solution with a high dielectric constant and
conductivity results in particles with smaller size [13]. This is explained by the scaling laws
which when rewritten, explains the inverse relationship between particle diameter (d) and
liquid conductivity (K) as shown in the equation below [13]:
d∝

1 1/6
K
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Besides the surface porosity, the size of the microparticles also plays a role in determining
the degradation rate of the microparticles which in turn affects release kinetics. Dunne et al
demonstrated that there was a linear relationship between PLGA microparticles size and
degradation rate [45]. It is more difficult for acidic byproducts to diffuse out of larger
microparticles, thus, resulting in a higher accumulation of the autocatalytic degradation
byproducts. The low pH in the polymer matrix results in an increase in the concentration of
protons which can catalyze ester hydrolysis which leads to an increase in autocatalytic
degradation of the remaining polymer matrix. The increase in degradation of the polymer
matrix results in an increase in drug release rates for these larger particles. In the release
study, we saw a drastic release at Day 14 for TM-50. This could have result from the change
of release from diffusion to release through erosion of the polymer at this point.
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The electrosprayed TMZ-loaded microparticles were able to better induce glioblastoma cell
death compared to TMZ delivered by itself which indicates that the biomaterial is able to
protect the bioactivity of the drug. The empty PLGA microparticles did not illicit a negative
response to the cells and thus, indicating, as expected, the polymer itself is not toxic to the
cells. MTT is often the first method used to evaluate the cytotoxic effect of drug (such as
TMZ) loaded particles on glioblastoma cell lines [18, 33]. In the future, other methods, such
as analysis with flow cytometry with annexin V for cell apoptosis, will be performed to
better understand glioblastoma cell response to the optimized particles.

CONCLUSIONS

Author Manuscript

The electrospraying method of fabricating PLGA microparticles resulted in particles with
high loading efficiency. Furthermore, this method resulted in ease in obtaining the particles
as tedious separation of the particles from the aqueous phase is not needed as in the
emulsion solvent evaporation method [13]. By using a larger volume of a solvent with higher
polarity (i.e. acetonitrile) which allows for a higher amount of hydrophilic TMZ to dissolve
into the polymer solution, higher drug loading could be achieved. However, the change in
solvents (which have different polarity and vapor pressure) used to fabricate the
microparticles not only changed the amount of drug loading, it also affected the surface
morphology, porosity and size of the particles which in turn affected the release kinetics of
the particles. Microparticles that were fabricated with high amount of acetonitrile and low
amount of DCM resulted in a high drug loading and had large pores and a smaller diameter
which led to an initial burst release and high cumulative release at the end of the study.
Microparticles that were fabricated with low amount of acetonitrile and high amount of
DCM had a low drug loading and had smaller pores or no pores and a larger diameter,
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resulting in a more sustained release. The electrosprayed microparticles were able to illicit a
cytotoxic response in U-87 MG glioblastoma cells at a lower concentration of drug
compared to the free drug. In conclusion, electrospraying is a promising method to fabricate
TMZ-loaded PLGA microparticles with high drug loading and loading efficiency that is able
to better sustain the bioactivity of loaded drugs compared to drugs that are delivered by
themselves. These particles can be used to delivery TMZ locally at a targeted site by
incorporating them into a biomaterial scaffold or by redesigning them to form a colloidal gel
which can be injected at the site of interest to form a scaffold by themselves [46]. These
particles can be also implanted to discrete areas by stereotaxy which will not require open
surgery [13].
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Figure 1.

SEM images of the different microparticles: A) TM-0, B) TM-25, C) TM-50 and D)
TM-100. The main images were taken at 2000× and the scale bar of these images represents
10 μm. The embedded images in B) and C) were taken at 6000× and the scale bar of these
images represents 2 μm.
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Figure 2.

Release kinetics of the different electrosprayed particles fabricated with different solvents.
The results are expressed as mean ± standard deviation for n = 3. Groups not connected with
the same letter are significantly different from each other (p < 0.05).
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Figure 3.
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Cell viability of U-87 MG glioblastoma cells exposed to the TMZ only, empty PLGA
microparticles only or TMZ loaded PLGA microparticles (i.e. TM-25) A) for 72 hours at
different drug concentrations based on drug loaded in the TMZ microparticles and B) at
different drug concentrations based on drug release from the TMZ microparticles at Day 4.
The results are expressed as mean ± standard deviation for n = 4. * indicates groups that are
significantly different (p < 0.05) from all other groups within the same drug concentration.
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Electrosprayed microparticles parameters and drug loading (%), loading efficiency (%) and mean diameter
(μm) of microparticles fabricated with different parameters. The results are expressed as mean ± standard
deviation for n = 3.
Groups

Solvent ratio
DCM : Acetonitrile

Amount of Drug Used for
Fabrication (mg)

Drug Loading (%)

Loading Efficiency (%)

Mean Diameter (μm)

TM-0

0 : 100

20

6.60 ± 0.20*

72.61 ± 2.30

2.94 ± 0.76

15

5.25 ±

0.21*

75.30 ± 3.12

3.51 ± 0.71

0.21*

81.52 ± 4.49

4.28 ± 1.13*

70.58 ± 7.40

11.50 ± 3.39*

TM-25

25 : 75

TM-50

50 : 50

10

3.88 ±

TM-100

100 : 0

4

1.38 ± 0.14*

*

indicates groups that are significantly different (p < 0.05) from all other groups.
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